Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Relapse/Refractory Diffuse Large B-cell Lymphoma
Conditions
Interventions
Rituximab Paclitaxel Ruxolitinib
Start Date
May 1, 2021
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2028
Last Updated
April 23, 2021
NCT05755087
NCT05672251
NCT06905509
NCT06859008
NCT05052528
NCT01959698
Lead Sponsor
National Health Research Institutes, Taiwan
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions